- Company
- KRPIA appoints new Chair Oh Dongwook of Pfizer Korea
- by Eo, Yun-Ho Jan 29, 2021 06:14am
- On Jan. 27, Korean Research-based Pharmaceutical Industry Association (KRPIA) announced Country Manager Oh Dongwook of Pfizer Pharmaceutical Korea is appointed as he 14th Chair of KRPIA leading the organization from February 2021. The new chair was elected as a member of the board in January 2016, and has been contributing in pushing KRPI
- InterView
- “34 years in drug industry, but now as a law firm advisor"
- by Eo, Yun-Ho Jan 28, 2021 05:59am
- A new advisor at Kang Han Law, Kwon Jaehong has 34 years of a long experience in the pharmaceutical industry. After joining JW Pharmaceutical sales department in 1998, Kwon moved to Bristol Myers Squibb (BMS) Korea in 1998 and was leading the Government Affairs and Market Access businesses until last August. But as he retired, he left t
- Company
- Going beyond antidiabetic, Forxiga to treat heart failure
- by Jan 28, 2021 05:59am
- AstraZeneca’s Forxiga has been approved in South Korea to treat diabetes and heart failure. The indication is obtained for the first time for a sodium-glucose co-transporter-2 (SGLT2) inhibitor. The industry experts noted, “Forxiga demonstrated reduction of cardiovascular death risk and hospitalization for heart failure in patients wit
- Company
- Leclaza’s lightning fast listing shocks global competitors
- by Eo, Yun-Ho Jan 27, 2021 06:15am
- As Yuhan Corporation dashes for the National Health Insurance (NHI) reimbursement talk on Leclaza (lazertinib), affected multinational pharmaceutical companies are tensing up. A Korean-made new drug Leclaza is to get reviewed by the Cancer Deliberation Committee in February, the related industry sees that the non-small cell lung cancer (
- Policy
- Can COVID-19 vaccine by the COVAX be quickly introduced?
- by Lee, Tak-Sun Jan 27, 2021 06:15am
- The health authorities said that it is possible to quickly introduce COVID-19 vaccine supplied from the COVAX Facility. This is because the MFDS has been participating in the COVAX Facility vaccine joint review since October at the request of the WHO. Pfizer's vaccine was pre-verified on the 31st of last month when the WHO approved Emergen
- Company
- NOAC prescription market growth stagnates
- by Kim, Jin-Gu Jan 27, 2021 06:15am
- The novel oral anticoagulant (NOAC) market seems to be plateauing after enjoying consistent two-digit growth for years. The outpatient prescription market marked a growth of almost 20 percent until 2019, but the growth shrunk down to 3 percent last year. Regardless of the decreased growth, Lixiana is still topping the market. Except for the
- Company
- 11 companies won consecutive patent disputes for Betmiga
- by Kim, Jin-Gu Jan 27, 2021 06:15am
- In the patent dispute over Betmiga PR (Mirabegron), an overactive bladder treatment with an annual prescription amount of ￦65 billion, generic companies won the first trial. From the standpoint of generic companies, including Hanmi and Chong Kun Dang, which have already launched generics, and are about to release generics, the obstacles r
- Policy
- AZ’s Vaccine Verification Advisory Committee Meeting held
- by Lee, Tak-Sun Jan 27, 2021 02:24am
- An advisory group meeting to verify the safety and effectiveness of AstraZeneca's COVID-19 vaccine will be held on the 31st of this month. In this meeting, external experts will participate in the clinical trial data. In addition, the Central Pharmaceutical Affairs Review Committee for COVID-19 treatment developed by Celltrion will be held
- Company
- Sales of Statin-Ezetimibe combination have risen sixfold
- by Chon, Seung-Hyun Jan 27, 2021 02:21am
- In the dyslipidemia treatment market, the combination drug market that combines 'Statin' and Ezetimibe' showed rapid growth. Despite COVID-19 outbreak, the sales continued high. In the past five years, sales have increased by six times. Hanmi's Rosuzet and MSD's Atozet led the uptrend. According to the drug research institute UBIST on the
- Company
- Yuhan’s Leclaza zooms through the NHI listing process
- by Eo, Yun-Ho Jan 26, 2021 06:00am
- Yuhan Corporation’s new drug Leclaza could break the record of receiving the National Health Insurance reimbursement the fastest as an anticancer treatment. After the South Korean health authority approved of the drug on Jan. 18, the company immediately entered a talk to list the drug. The pharmaceutical industry source reported the Hea
